Use and safety of long-acting β2-agonists for pediatric asthma

Hajer Elkout, James S McLay, Colin R Simpson, Peter J Helms

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Asthma guidelines recommend the use of long-acting β2-agonists (LABAs) as the preferred add-on therapy for adults and children over 5 years of age when asthma is inadequately controlled by inhaled corticosteroids alone. It has been suggested that LABA use may be associated with an increased risk of morbidity and mortality; however, this view is controversial since study findings have been inconsistent. While the safety profile of LABA monotherapy has been questioned, the value of concomitant inhaled corticosteroids to eliminate possible risks remains unproven. There is a paucity of efficacy and safety data for LABA use in children, and existing evidence is not sufficiently convincing to demonstrate a clear position for LABAs in the management of childhood asthma. The main aims of this article are to place LABAs in context in the management of childhood asthma and evaluate the current evidence for safety and efficacy.
Original languageEnglish
Pages (from-to)295-310
Number of pages16
JournalPediatric Health
Volume4
Issue number3
DOIs
Publication statusPublished - Jun 2010

Fingerprint

Asthma
Pediatrics
Safety
Adrenal Cortex Hormones
Guidelines
Morbidity
Mortality
Therapeutics

Cite this

Use and safety of long-acting β2-agonists for pediatric asthma. / Elkout, Hajer; McLay, James S; Simpson, Colin R; Helms, Peter J.

In: Pediatric Health, Vol. 4, No. 3, 06.2010, p. 295-310.

Research output: Contribution to journalArticle

Elkout, Hajer ; McLay, James S ; Simpson, Colin R ; Helms, Peter J. / Use and safety of long-acting β2-agonists for pediatric asthma. In: Pediatric Health. 2010 ; Vol. 4, No. 3. pp. 295-310.
@article{b7b1a8821bc44eed9935bc42062fbd3a,
title = "Use and safety of long-acting β2-agonists for pediatric asthma",
abstract = "Asthma guidelines recommend the use of long-acting β2-agonists (LABAs) as the preferred add-on therapy for adults and children over 5 years of age when asthma is inadequately controlled by inhaled corticosteroids alone. It has been suggested that LABA use may be associated with an increased risk of morbidity and mortality; however, this view is controversial since study findings have been inconsistent. While the safety profile of LABA monotherapy has been questioned, the value of concomitant inhaled corticosteroids to eliminate possible risks remains unproven. There is a paucity of efficacy and safety data for LABA use in children, and existing evidence is not sufficiently convincing to demonstrate a clear position for LABAs in the management of childhood asthma. The main aims of this article are to place LABAs in context in the management of childhood asthma and evaluate the current evidence for safety and efficacy.",
author = "Hajer Elkout and McLay, {James S} and Simpson, {Colin R} and Helms, {Peter J}",
year = "2010",
month = "6",
doi = "10.2217/phe.10.31",
language = "English",
volume = "4",
pages = "295--310",
journal = "Pediatric Health",
number = "3",

}

TY - JOUR

T1 - Use and safety of long-acting β2-agonists for pediatric asthma

AU - Elkout, Hajer

AU - McLay, James S

AU - Simpson, Colin R

AU - Helms, Peter J

PY - 2010/6

Y1 - 2010/6

N2 - Asthma guidelines recommend the use of long-acting β2-agonists (LABAs) as the preferred add-on therapy for adults and children over 5 years of age when asthma is inadequately controlled by inhaled corticosteroids alone. It has been suggested that LABA use may be associated with an increased risk of morbidity and mortality; however, this view is controversial since study findings have been inconsistent. While the safety profile of LABA monotherapy has been questioned, the value of concomitant inhaled corticosteroids to eliminate possible risks remains unproven. There is a paucity of efficacy and safety data for LABA use in children, and existing evidence is not sufficiently convincing to demonstrate a clear position for LABAs in the management of childhood asthma. The main aims of this article are to place LABAs in context in the management of childhood asthma and evaluate the current evidence for safety and efficacy.

AB - Asthma guidelines recommend the use of long-acting β2-agonists (LABAs) as the preferred add-on therapy for adults and children over 5 years of age when asthma is inadequately controlled by inhaled corticosteroids alone. It has been suggested that LABA use may be associated with an increased risk of morbidity and mortality; however, this view is controversial since study findings have been inconsistent. While the safety profile of LABA monotherapy has been questioned, the value of concomitant inhaled corticosteroids to eliminate possible risks remains unproven. There is a paucity of efficacy and safety data for LABA use in children, and existing evidence is not sufficiently convincing to demonstrate a clear position for LABAs in the management of childhood asthma. The main aims of this article are to place LABAs in context in the management of childhood asthma and evaluate the current evidence for safety and efficacy.

U2 - 10.2217/phe.10.31

DO - 10.2217/phe.10.31

M3 - Article

VL - 4

SP - 295

EP - 310

JO - Pediatric Health

JF - Pediatric Health

IS - 3

ER -